Lipocine (STU:2VT0) Other Current Payables: €0.00 Mil (As of Mar. 2026)


STU:2VT0 Lipocine Inc STU:2VT0
52 GF Score
Price €3.94
GF Value €2.99
! 4 Warning Signs
View Full Analysis

What is Lipocine Other Current Payables?

Lipocine STU:2VT0 52 Other Current Payables is €0.00 Mil as of Mar. 2026. GuruFocus rates STU:2VT0 with a GF Score™ of 52/100 and a GF Value™ of €2.99. The stock has 4 warning signs investors should review.

Lipocine's Other Current Payables for the quarter that ended in Mar. 2026 was €0.00 Mil.


Lipocine Other Current Payables Related Terms


Lipocine Other Current Payables Historical Data

* Premium members only.

The historical data trend for Lipocine's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lipocine Other Current Payables Chart

Lipocine Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Lipocine Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:2VT0
52GF Score
Lipocine Inc STU:2VT0
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lipocine Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of €0.00 Mil mean?
Lipocine (STU:2VT0) has a Other Current Payables of €0.00 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Lipocine and its competitors.
Is Lipocine's Other Current Payables too high?
Lipocine's current Other Current Payables is €0.00 Mil. Overall, Lipocine has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Lipocine's Other Current Payables compare to NCEL and PTN?
Lipocine's Other Current Payables of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Lipocine and its competitors. Lipocine's current Other Current Payables is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipocine stock overvalued right now?
Lipocine (STU:2VT0) has a current Other Current Payables of €0.00 Mil. The stock's GF Value™ is €2.99, compared to a current price of €3.94 — trading 31.9% above its estimated fair value. The current Other Current Payables is €0.00 Mil. Lipocine's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Lipocine (STU:2VT0), the current Other Current Payables is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lipocine (STU:2VT0) Overvalued in 2026?

Based on GuruFocus' analysis, Lipocine stock appears to be overvalued. The current stock price of €3.94 is trading 31.9% above its estimated GF Value™ of €2.99.

Key valuation signals for STU:2VT0:

  • Other Current Payables: €0.00 Mil
  • GF Value™: €2.99 vs. price of €3.94 (31.9% above fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the STU:2VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lipocine Business Description

Other Exchanges LPCN:USA
Address 675 Arapeen Drive, Suite 202, Salt Lake City, UT, USA, 84108
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
52GF Score

Get the complete analysis for STU:2VT0

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.94
Price
€2.99
GF Value